Bezlotoxumab
Bezlotoxumab is a monoclonal antibody used to prevent recurrence of Clostridioides difficile (C. diff) infection in adults at high risk for recurrence. It is administered as a single intravenous infusion alongside standard antibiotic treatment for C. diff infection. This medication does not treat active C. diff infection but helps reduce the risk of the infection coming back.
A monoclonal antibody that prevents C. difficile infection recurrence by neutralizing toxin B.
Key facts at a glance
- ATC
- J06BC03
- RxNorm
- 1855048
- Generic
- Bezlotoxumab
- Class
- atc-j06
- Brands
- Zinplava
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 500mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 250mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 400mg daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
9 groupspregnancy
generalavoid if possible
use only if potential benefits justify potential risks to fetus; insufficient data available
standard prenatal monitoring
pregnancy
first trimesteravoid if possible
avoid use unless benefits outweigh risks
regular fetal monitoring
lactation
generalno adjustment
breastfeeding not recommended during treatment and for 6 months after; decision should consider infant benefits and mother benefits
monitor infant for adverse effects
geriatric
over 65no adjustment
no dose adjustment required for patients over 65 years; efficacy and safety consistent with younger adults
standard clinical monitoring
pediatric_age
under 18 yearsnot recommended
not approved for patients under 18 years of age; safety and efficacy not established
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
renal_impairment
mild to moderateno adjustment
no dose adjustment required for mild to moderate renal impairment based on pharmacokinetic characteristics
standard clinical monitoring
renal_impairment
severeuse with caution
use with caution; limited clinical data available
close clinical monitoring recommended
hepatic_impairment
mild to moderateno adjustment
no dose adjustment anticipated based on monoclonal antibody metabolism
standard clinical monitoring
hepatic_impairment
severeuse with caution
use with caution; not studied in severe hepatic impairment
close clinical monitoring recommended
Statistics and clinical data
Drug class
Bezlotoxumab is a fully human monoclonal antibody
Common uses
Indicated to reduce recurrence of C. difficile infection in high-risk patients
FDA approval year
Initial FDA approval date for Bezlotoxumab (Zinplava)
Mechanism of action
Monoclonal antibody that neutralizes C. difficile toxin B
Prevention of recurrence of Clostridioides difficile infection in adults at high risk for recurrence, given as adjunct to antibacterial therapy.
Human monoclonal antibody that binds specifically to C. difficile toxin B, neutralizing its effects and preventing toxin-mediated damage to cells.
Administered as a single 60-minute intravenous infusion. Does not have antibacterial activity and is not indicated for treatment of active C. diff infection. Heart failure has been observed as a potential adverse reaction in clinical trials; use with caution in patients with known heart failure.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy